Blue Protein

Blue Protein is a biotechnology company specializing in the production of high-quality recombinant proteins using a proprietary silkworm-based expression system. By leveraging the Bombyx mori (silkworm) platform, the company achieves high yields and complex post-translational modifications for proteins that are typically difficult to express in conventional mammalian or bacterial systems. Their portfolio includes research reagents, diagnostic antigens, and custom protein synthesis services tailored for the pharmaceutical and life sciences industries. The company gained significant prominence for its rapid production of SARS-CoV-2 antigens and continues to support drug discovery and diagnostic development through its unique biomanufacturing capabilities. Blue Protein operates as a spin-off from Tokushima University, maintaining a strong focus on innovative protein engineering.